The History of 5-ASA compounds and their use in ulcerative colitis - Trailblazing discoveries in gastroenterology

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 4, 2013, Pages 375-377

  Mayberry, John ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; BALSALAZIDE; ENEMA; MESALAZINE; OLSALAZINE; QUADRASA; SALAZOSULFAPYRIDINE; SULFAMIDOCHRYSOIDINE; SULFANILAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

CONTROLLED CLINICAL TRIAL (TOPIC); EDITORIAL; HUMAN; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; DIFFUSION OF INNOVATION; GASTROENTEROLOGY; GASTROINTESTINAL AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MESALAMINE;

EID: 84890461976     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Woods DD. The relation of p-amainobenzoic acid to the mechanism of the actions of sulphanilamide. Br J Exp Pathol 1940;21:74-90.
2. Sherwood Taylor F. The Conquest of Bacteria. From 606 to 693. Secker and Warburg, London 1940.
3. Mann J. The Elusive Magic Bullet. The search for the perfect drug. Oxford University Press, New York 1999.
4. Sheldon P. The Fall and Rise of Aspirin. The Wonder Drug. Brewin Books Ltd, Studley, UK, 2007.
5. Svartz N. Salazopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulphanilamide preparations. Acta Med Scand 1942;110:577-598.
6. Bargen JA. The Modern Management of Colitis. Charles C Thomas, Springfield, Illinois, USA 1943.
7. Bargen JA. Treatment of ulcerative colitis with salicylazosulfapyridine (salazopyrin). Med Clin North Am 1949;33:935-942.
8. Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Avery Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1: 185-188.
9. Dissanayake AS, Truelove SC. A controlled therapeutic trial of longterm maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 1973;14:923-926.
10. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-895.
11. Dew MJ, Ryder RE, Evans N, Evans BK, Rhodes J. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol 1983;16:185-187.
12. http://www.ferring.com/NR/rdonlyres/A49FC14A-A7F6-47E9-B926-DD75CF9598BB/0/pentasa_highlights.pdf (Accessed 28/11/2010).
13. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 1983;28:609-615.
14. Lennard-Jones JE. Historical development of balsalazide (Colazide®). Research and Clinical Forums 1998;20:75-83.
15. McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988;2:237-243.
16. Campieri A, Lanfranchi GA, Bertoni F, et al. Double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 1984;29:204-208.
17. Marteau P, Halphen M. Étude comparative ouverte randomisée de efficacité et de la tolérance de lavements de 2 g d acide 4-aminosalicylique (4-ASA) et de 1 g d acide 5-amino-salicylique (5-ASA) dans les formes basses de rectocolite hémorragique. Gastroenterol Clin Biol 1995;19:31-35.
18. Selby WS, Bennett MK, Jewell DP. Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas. Digestion 1984;29:231-234.
19. Nilsson A, Danielsson A, Lofberg R, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol 1995;90:381-387.
20. Moshkovska T, Mayberry JF. Duration of treatment with 5-aminosalicylic acid compounds. World J Gastroenterol 2007;13:4310-4315.
21. Villa R, Pedrani M., Ajani M, Fossati L. EP 1 183 014 B1 Controlled Release and Taste Masking Pharmaceutical Compositions 2000. Granted 9/10/2003.
22. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflam Bowel Dis 2005;11:421-427.
23. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107:117-120.
24. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Longterm therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-1183.
25. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-153.